Muenster, Germany

Stefanie Krenzlin

USPTO Granted Patents = 3 


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017-2021

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Stefanie Krenzlin

Introduction

Stefanie Krenzlin is a notable inventor based in Muenster, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of oral dosage forms for treating various diseases. With a total of three patents to her name, her work has the potential to impact the treatment of conditions such as multiple sclerosis and psoriasis.

Latest Patents

Krenzlin's latest patents focus on improved oral dosage forms of methyl hydrogen fumarate and its prodrugs. These innovations not only enhance the delivery of the medication but also provide methods for treating diseases like multiple sclerosis and psoriasis. The advancements in her patents reflect her commitment to improving patient outcomes through effective pharmaceutical solutions.

Career Highlights

Throughout her career, Krenzlin has worked with reputable companies in the pharmaceutical industry, including Arbor Pharmaceuticals and Xenoport. Her experience in these organizations has allowed her to refine her skills and contribute to significant advancements in drug formulation and delivery.

Collaborations

Krenzlin has collaborated with various professionals in her field, including Sami Karaborni and Sarina Grace Harris Ma. These partnerships have likely enriched her research and development efforts, fostering innovation in her projects.

Conclusion

Stefanie Krenzlin's work exemplifies the impact of innovation in the pharmaceutical industry. Her patents and collaborations highlight her dedication to advancing medical treatments and improving the quality of life for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…